Product Details

Uniprot No.

Target Names

Alternative Names

Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1), MAP2K1, MEK1 PRKMK1

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human MEK1

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

3F10

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IHC, IP

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200
IP	1:200-1:1000

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

MAP2K1, also known as MEK1, serves as a critical dual-specificity kinase in the MAPK/ERK signaling cascade, directly phosphorylating and activating ERK1 and ERK2. This central position in mitogenic signal transduction makes MAP2K1 an essential target for researchers investigating cell proliferation, differentiation, and survival pathways, with particular relevance to oncology studies where aberrant MAPK signaling frequently drives tumor progression.

This recombinant monoclonal antibody, clone 3F10, offers the reproducibility that demanding signal transduction research requires. Generated against a synthetic peptide derived from human MEK1 and produced using recombinant technology, each lot delivers sequence-defined consistency that eliminates the variability often encountered with traditional hybridoma-derived antibodies. This reliability proves especially valuable when tracking subtle changes in MAP2K1 expression across experimental conditions or when building datasets over extended study periods.

Validation across multiple platforms demonstrates genuine experimental flexibility. Western blot analysis confirms robust detection at the expected 44 kDa molecular weight across diverse human cell lines including HeLa, HEK293, A549, and U87, with effective working dilutions ranging from 1:500 to 1:5000. Immunohistochemistry testing in paraffin-embedded human colon cancer tissue using citrate buffer antigen retrieval shows clear staining at 1:100 dilution, supporting tissue-based expression studies. Immunoprecipitation validation in HeLa lysates confirms the antibody's utility for protein interaction studies and enrichment workflows.

The affinity-purified rabbit IgG format and verified performance across ELISA, western blot, immunohistochemistry, and immunoprecipitation applications position this antibody as a versatile tool for comprehensive MAP2K1 characterization in signal transduction research and cancer biology investigations.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Activates BRAF in a KSR1 or KSR2-dependent manner; by binding to KSR1 or KSR2 releases the inhibitory intramolecular interaction between KSR1 or KSR2 protein kinase and N-terminal domains which promotes KSR1 or KSR2-BRAF dimerization and BRAF activation. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis.

Gene References into Functions

Upregulation of miR101 inhibited DLBCL cell proliferation and facilitated apoptosis by inhibiting the expression of MEK1. PMID: 30365139
Somatic activating mutations in MAP2K1 cause melorheostosis. PMID: 29643386
Here the authors identified a direct interaction of both MEK1 and MEK2 with AKT. The interaction between MEK and AKT affects cell migration and adhesion, but not proliferation. The specific mechanism of action of the MEK-AKT complex involves phosphorylation of the migration-related transcription factor FoxO1. PMID: 28225038
Activating mutations enhance the rate of MEK1 phosphorylation by Raf. Activating mutations affect thermal stability of MEK1 and its activity toward ERK2. PMID: 29018093
Data indicate two atypical hairy cell leukemia (HCLc)- and hairy cell leukemia variant (HCLv)-like cases with clinically detected mitogen-activated protein kinase kinase 1 (MAP2K1) mutations. PMID: 27241017
Reactive oxygen species-mediated EGFR/MEK/ERK/HIF-1A loop regulates glucose metabolism in pancreatic cancer. PMID: 29702094
High MEK1 expression is associated with urinary bladder cancer metastasis. PMID: 28534984
we detected mutually exclusive KRAS and MAP2K1 mutations in one-third of cases of Rosai-Dorfman disease PMID: 28664935
The rs1549854 and rs1432441 polymorphisms of the MAP2K1 gene may be associated with major depressive disorder, especially in females. PMID: 28688265
MEK1 does not act as a general tumor suppressor in leukemogenesis. Rather, its effects strongly depend on the genetic context (RAS versus MYC-driven leukemia) and on the cell type involved. PMID: 27741509
Report a synthetic lethal interaction of cetuximab in combination with MEK1/2 inhibition for the NRAS mutant subgroup of metastatic colorectal cancer. PMID: 27636997
High MEK1 expression is associated with liver cancer. PMID: 26967560
The BRAF/MAP2K1-mut LCH cells had a more immature state than BRAF/MAP2K1-wt LCH cells. Authors also found the BRAFV600E and MAP2K1 mutations were significantly associated with pERK expression. PMID: 27597420
There are no other biomarkers correlated with treatment responses following MEK1/2 inhibition. PMID: 27956260
High MEK1 expression is associated with neuroblastoma. PMID: 28687621
mutations in MAP2K1, which are frequently associated with neurological complications and intellectual disability, can be associated with a milder clinical and neurocognitive profile more typical of individuals with Noonan syndrome. Variability of expression may arise from a complex interplay between RAS/MAPK pathway genotype, epigenetics, medical and obstetric factors, and environmental influences. PMID: 27862862
High MEK1 expression is associated with infant acute lymphoblastic leukemia. PMID: 27588400
Data show that combined therapy using HER2 inhibitor and BRAF/MEK inhibitor presented more significant redifferentiation effect on papillary thyroid cancer cells harboring BRAFV600E than BRAF/MEK inhibitor alone. PMID: 28423638
MEK1 is constitutively and mainly phosphorylated at the Thr-292, Ser-298, Thr-386, and Thr-388 residues in vivo, and combinations of phosphorylations at these four residues produce at least six phosphorylated variants of MEK1. The phosphorylation statuses of Thr-292, Ser-298, Thr-386, and Thr-388 residues vary widely during activation and deactivation of the MAPK pathway. PMID: 27169363
TNFRSF14 and MAP2K1 mutations are the most frequent genetic alterations found in pediatric-type follicular lymphoma (PTFL) and occur independently in most cases, suggesting that both mutations might play an important role in PTFL lymphomagenesis. PMID: 28533310
There was no statistically significant association between BRAF or MAP2K1 mutation and anatomic site, unifocal versus multifocal presentation, or clinical outcome in Langerhans cell histiocytosis. PMID: 26980021
High MEK1 expression is associated with inflammation. PMID: 28178421
Lgr4 is a critical positive factor for skin tumorigenesis by mediating the activation of MEK1/ERK1/2 and Wnt/beta-catenin pathways. PMID: 27693558
somatic mutations in MAP2K1 are a common cause of extracranial arteriovenous malformation PMID: 28190454
MEK1 mutation is associated with central nervous system metastases of non-small cell lung cancer. PMID: 26860843
The MAP2K1 mutation analysis of three hairy cell leukemia cases, one hairy cell leukemia-variant case, and three splenic marginal zone lymphoma cases revealed negative results. PMID: 25729732
Data show that mitogen-activated protein kinase kinases MEK1/2 inhibitor pimasertib (MEKI) sensitized the cells to apoptosis through its ability to promote a G1 cell cycle arrest. PMID: 26625317
Specific inhibition of BRAF oncogene, MEK or p38 signaling was associated with decreases in DIO3 expression in papillary thyroid cancer cells PMID: 26825960
Data show that Ba/F3 cells transformed with mutant HRAS protien indicated equal sensitivity towards Map kinase kinase (MEK) and mTOR serine-threonine kinase (mTOR) inhibition. PMID: 26544513
Our data demonstrate that MEK inhibitors can inhibit breast cancer stem cells and may have clinical potential for the prevention of metastasis in certain cases in which tumors are MAPK dependent. PMID: 26384399
Data show that src kinases (SRC) and mitogen-activated protein kinase kinase 1 (MEK) co-inhibition by saracatinib and PD0325901 respectively can be broadly effective in tumor growth control of a wide panel of non-small cell lung cancer (NSCLC) cell lines. PMID: 26358373
at clinically relevant concentrations, cDDP binds to and inhibits MEK1/2 and both the binding and inhibitory activity are related to its interaction with Cu bound to MEK1/2 PMID: 26155939
Studies indicate that concurrent inhibition of proto-oncogene protein B-raf (BRAF) and Map kinase kinase (MEK) improved the most effective therapeutic modality as compared as single BRAF or MEK inhibition for patients with metastatic melanoma (MM). PMID: 26143635
Findings suggest that triple therapy directed against BRAF/MEK/ErbB3 may be able to provide durable control of BRAF mutated metastatic melanoma. PMID: 26208478
MEK1 levels are upregulated at transcriptional level whereas MEK2 levels are downregulated at posttranslational level. PMID: 26163823
NOTCH1, TP53, and MAP2K1 mutations in splenic diffuse red pulp small B-cell lymphoma are associated with progressive disease. PMID: 26426381
MEK1/2 inhibitor trametinib showed similar PFS and a response rate as docetaxel in patients with previously treated KRAS-mutant-positive non-small cell lung carcinoma. PMID: 25722381
Findings establish that the convergence of 2 distinct Ras effector pathways on mammalian target of rapamycin signaling maintains neurofibromatosis type 1 mouse optic glioma growth. PMID: 25534823
MEK1 Mutations are associated with Low-grade Serous Ovarian Cancer. PMID: 26324360
SGK1 inhibits intestinal epithelial cell apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis. PMID: 26034353
MEK1 mutations define a distinct subset of lung cancers ( approximately 1%) with potential sensitivity to MEK inhibitors. Mutations are predominantly transversions, in keeping with a strong association with smoking. PMID: 25351745
Data show that licochalcone A (LicoA) suppresses solar UV-induced cyclooxygenase (COX-2) expression by acting as a potent inhibitor of enzymes PI3K, MEK1, and B-Raf. PMID: 25710724
Langerhans cell histiocytosis cells can harbor additional genetic alterations in the RAS-RAF-MEK pathway which, in the case of MAP2K1, may be responsible for ERK activation in a wild type BRAF setting. PMID: 25899310
our data indicate that preexisting MEK1(P124) mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of patients with BRAF-mutant melanoma likely to benefit from combination therapies PMID: 25370473
MAP2K1 missense mutations were found in 2 of 11 patients with cadiofaciocutaneous syndrome: Pro124Gln and Asp67Asn. PMID: 25194980
We documented three novel mutations in the BRAF gene in cardio-facio-cutaneous syndrome patients and correlated clinical findings with causative mutations in the BRAF or MEK1/MEK2 genes PMID: 25463315
MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. PMID: 25408231
Treatment of cells with sirtuin inhibitors, or siRNA knockdown of SIRT1 or SIRT2 proteins, increases MEK1 acetylation and subsequent phosphorylation of the extracellular signal-regulated kinase. PMID: 24681949
MEK1/2 inhibitor potentiated the anti-tumor effects of cisplatin in KRAS-dependent lung cancer cells and an animal model through inhibition of BIM degradation PMID: 25541062
Findings support the hypothesis that BDNF and MEK1 mRNA expression levels are more obviously decreased in patients with treatment-resistant depression. PMID: 24709918

Hide All

Involvement in disease

Cardiofaciocutaneous syndrome 3 (CFC3)

Subcellular Location

Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body. Cytoplasm. Nucleus. Membrane; Peripheral membrane protein.

Protein Families

Protein kinase superfamily, STE Ser/Thr protein kinase family, MAP kinase kinase subfamily

Tissue Specificity

Widely expressed, with extremely low levels in brain.

Database Links

HGNC: 6840

OMIM: 176872

KEGG: hsa:5604

STRING: 9606.ENSP00000302486

UniGene: Hs.145442

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA225579A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: Hela whole cell lysate, 293 whole cell lysate, A549 whole cell lysate, U87 whole cell lysate All lanes: MAP2K1 antibody at 1:2000 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 44, 41 kDa Observed band size: 44 kDa IHC image of CSB-RA225579A0HU diluted at 1:100 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB. Immunoprecipitating MAP2K1 in Hela whole cell lysate Lane 1: Rabbit control IgG instead of CSB-RA225579A0HU in Hela whole cell lysate. For western blotting,a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000) Lane 2: CSB-RA225579A0HU(2µg)+ Hela whole cell lysate(500µg) Lane 3: Hela whole cell lysate (10µg)
Have Questions?	Leave a Message or Start an on-line Chat

MAP2K1 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background